Volume | 1,102,682 |
|
|||||
News | - | ||||||
Day High | 23.0565 | Low High |
|||||
Day Low | 22.00 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Beam Therapeutics Inc | BEAM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
22.08 | 22.00 | 23.0565 | 22.72 | 21.74 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
14,681 | 1,102,682 | US$ 22.52 | US$ 24,833,756 | - | 16.95 - 49.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:56:22 | 1 | US$ 23.21 | USD |
Beam Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.86B | 81.66M | - | 377.71M | -132.53M | -1.62 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Beam Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BEAM Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.77 | 23.0565 | 20.84 | 21.57 | 1,359,796 | 0.95 | 4.36% |
1 Month | 29.75 | 30.12 | 20.84 | 24.72 | 1,648,599 | -7.03 | -23.63% |
3 Months | 27.55 | 49.50 | 20.84 | 31.90 | 1,547,430 | -4.83 | -17.53% |
6 Months | 21.33 | 49.50 | 18.8501 | 29.20 | 1,474,010 | 1.39 | 6.52% |
1 Year | 30.68 | 49.50 | 16.95 | 28.39 | 1,197,742 | -7.96 | -25.95% |
3 Years | 82.95 | 138.5219 | 16.95 | 47.31 | 1,023,825 | -60.23 | -72.61% |
5 Years | 19.19 | 138.5219 | 13.00 | 49.89 | 915,805 | 3.53 | 18.39% |
Beam Therapeutics Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. |